Smolen JS, et al. - This study presents 2017 update of the 2012 recommendations for treating axial and peripheral spondyloarthritis (SpA), developed by a task force of rheumatologists, dermatologists, patients and a health professional, based on the results of a systematic literature review and expert opinion. A single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA), was proposed. Broadly supported principal targets for the treatment of PsA included remission/inactive disease and, alternatively, low/minimal disease activity. Although not supported by all, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended as the tools to evaluate the patients on the path to the target. Shared decision-making between the clinician and the patient was considered crucial. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field.